Follow
Alexander Drilon
Alexander Drilon
Verified email at mskcc.org - Homepage
Title
Cited by
Cited by
Year
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ...
New England Journal of Medicine 378 (8), 731-739, 2018
24492018
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
13282020
NTRK fusion-positive cancers and TRK inhibitor therapy
E Cocco, M Scaltriti, A Drilon
Nature reviews Clinical oncology 15 (12), 731-747, 2018
11962018
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
9932019
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
7652017
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ...
The Lancet Oncology 21 (4), 531-540, 2020
7602020
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
6662018
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...
New England Journal of Medicine 383 (9), 813-824, 2020
6562020
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
PK Paik, A Drilon, PD Fan, H Yu, N Rekhtman, MS Ginsberg, L Borsu, ...
Cancer discovery 5 (8), 842-849, 2015
6072015
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ...
New England Journal of Medicine 383 (9), 825-835, 2020
5932020
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
5632017
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
A Drilon, L Wang, A Hasanovic, Y Suehara, D Lipson, P Stephens, J Ross, ...
Cancer discovery 3 (6), 630-635, 2013
5462013
Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
JAMA oncology 5 (10), 1411-1420, 2019
4822019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ...
Modern Pathology 33 (1), 38-46, 2020
4492020
Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532, 2018
4432018
Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions
JF Hechtman, R Benayed, DM Hyman, A Drilon, A Zehir, D Frosina, ...
The American journal of surgical pathology 41 (11), 1547-1551, 2017
4182017
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ...
The Lancet Oncology 17 (12), 1653-1660, 2016
4072016
Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets
N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ...
Clinical Cancer Research 22 (14), 3618-3629, 2016
4052016
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
4012020
Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations
A Drilon, SHI Ou, BC Cho, DW Kim, J Lee, JJ Lin, VW Zhu, MJ Ahn, ...
Cancer discovery 8 (10), 1227-1236, 2018
3812018
The system can't perform the operation now. Try again later.
Articles 1–20